Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province

Identifying actionable driver mutations in NSCLC has enabled the broad adoption of precision oncology approaches into routine clinical practice. Improvements in testing infrastructure and tissue acquisition processes have made biomarker analysis increasingly available to patients diagnosed with NSCLC. While the benefit of these new systemic anti-cancer therapy (SACT) regimes was initially demonstrated in clinical trials, real world data are necessary to evaluate their societal contribution and confirm value to the health care system.